CagriSema would be the first combo GLP-1 if it’s approved, while orforglipron would be the first GLP-1 pill approved for ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

UnitedHealth Group (UNH 1.05%) and Eli Lilly (LLY +1.45%) are two of the largest and most powerful healthcare companies in ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

The Huntsville Planning Commission voted to rezone 73.40 acres east of Greenbrier Road and north of Interstate 565 in ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

U.S. Olympians Elana Meyers Taylor and Gabby Thomas participated in a social video, drawing a throughline between their ...